This study provided a partial molecular biological basis for iruplinalkib in the treatment of crizotinib-resistant or non-resistant ALK-positive NSCLC or first-line ALK- and ROS1-positive NSCLC. The gene discussed is ALK; the disease is non-small cell lung carcinoma.